SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-005514 to Savara Inc (SVRA) (CIK 0001160308) (SVRA)

Savara Inc (SVRA) (CIK 0001160308)
Date: May 14, 2024 · CIK: 0001160308 · Accession: 0000000000-24-005514

AI Filing Summary & Sentiment

File numbers found in text: 333-279274

Date
May 14, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Savara Inc (SVRA) (CIK 0001160308)

Letter

United States securities and exchange commission logo May 14, 2024 Matthew Pauls Chief Executive Officer Savara Inc. 1717 Langhorne Newtown Road Suite 300 Langhorne, PA 19047 Re:Savara Inc. Registration Statement on Form S-3 Filed May 9, 2024 File No. 333-279274 Dear Matthew Pauls: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Shawn M. Turner, Esq.

Show Raw Text
United States securities and exchange commission logo
May 14, 2024
Matthew Pauls
Chief Executive Officer
Savara Inc.
1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
Re:Savara Inc.
Registration Statement on Form S-3
Filed May 9, 2024
File No. 333-279274
Dear Matthew Pauls:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Shawn M. Turner, Esq.